Miambutol (Ethambutol Hydrochloride)

Ethambutol blocks the arabinosyl transferase enzyme that is essential for building the mycobacterial cell wall. By preventing arabinogalactan synthesis, the drug weakens the cell wall, inhibiting bacterial growth and making the organism more susceptible to the actions of companion drugs.

The dosage of Miambutol is individualized by the prescribing clinician based on the patient’s weight, age, renal function and the overall treatment regimen. Health‑care professionals determine the exact amount and frequency according to current tuberculosis treatment guidelines.

The pregnancy category for ethambutol is not definitively established. Use during pregnancy or lactation should only occur when the potential benefit justifies any possible risk to the fetus or infant, and it must be decided by a qualified health‑care provider.

To request Miambutol, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ethambutol differs from isoniazid and rifampicin by its mechanism—targeting cell‑wall arabinosyl transferase rather than mycolic acid synthesis or RNA polymerase. It is generally less hepatotoxic than isoniazid but carries a higher risk of optic neuritis, making visual monitoring essential during therapy.

Miambutol tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in damp or excessively hot environments.

Miambutol is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable absorption. Patients should follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

The most critical adverse effect is optic neuritis, which can lead to irreversible visual loss if not identified early. Other serious concerns include severe hypersensitivity reactions, hepatic injury, and rare skin disorders such as Stevens‑Johnson syndrome. Prompt reporting of visual changes or systemic symptoms is vital.

Miambutol is contraindicated in individuals with known hypersensitivity to ethambutol or any component of the formulation. Patients with severe renal impairment may require dose adjustment or alternative therapy, and those with pre‑existing optic nerve disease should avoid the drug due to heightened risk of visual toxicity.